miR-495-3p mimics suppress the expression of ER chaperone GRP78 and inhibit the proliferation and migration of breast cancer (MDA-MB-231) cells, reducing pirarubicin resistance by inactivating AKT expression, which is reversed by miR-495-3p inhibition [56]. Here, AKT1 is linked to breast cancer.